Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Micardis® (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
This post-marketing surveillance study was designed to supplement under conditions of normal
clinical practice the data on the safety, tolerability and efficacy of Micardis® collected
during the clinical studies.
Clinical Details
Official title: Safety, Tolerability and Efficacy of Micardis® (Telmisartan) in Patients With Essential Hypertension
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Indicence of ulceraIncidence of gastrointestinal (GI) bleedings
Secondary outcome: Incidence of adverse events (GI-complaints inclusive)Change from baseline in office blood pressure Response rate
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients of both sexes with essential hypertension and a minimum age of 18 years
Exclusion Criteria: (Not applicable)
Locations and Contacts
Additional Information
Starting date: January 1999
Last updated: July 7, 2014
|
